Talking About Tumors

Chapter 1

Chapter 1: Gastrointestinal Malignancies

Colon, gastroesophageal, pancreatic, biliary, rectal, anal, ampullary, and related GI oncology topics.

← Back to episode archive

S01 E01

Metastatic Colon Cancer, An Overview of Management and Fundamentals of Systemic Therapy

Open episode on Buzzsprout

Show notes

Topics covered

  1. Clinical presentations of metastatic colon cancer
  2. ECOG performance status
  3. 5-fluorouracil and capecitabine
  4. Doublet Regimens (FOLFOX/FOLFIRI and derivatives)
  5. FOLFOXIRI
  6. Considerations for elderly/frail patients
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Cremolini C, et al. Lancet Oncol. 2020;21(4):497-507. doi:10.1016/S1470-2045(19)30862-9
  2. 2. Cremolini C et al. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9
  3. 3. Sobrero AF et al. J Clin Oncol. 2016;15(1):368-381. doi:10.1200/JCO.1997.15.1.368
  4. 4. Pinedo HM, Peters GFJ. J Clin Oncol. 1988;6(10):1653-1664. doi:10.1200/JCO.1988.6.10.1653
  5. 5. Loriot MA, et al. Bulletin du Cancer. 2018;105(4):397-407. doi:10.1016/J.BULCAN.2018.02.001
  6. 6. Pachman DR et al. J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533
  7. 7. Eonard L et al. NEJM. 2009;343(13):905-914. doi:10.1056/NEJM200009283431302
  8. 8. Falcone A et al. J Clin Oncol. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928
  9. 9. Tournigand C et al. J Clin Oncol. 2004;22(2):229-237. doi:10.1200/JCO.2004.05.113
  10. 10. Group NGTAT. J Clin Oncol. 2016;10(6):904-911. doi:10.1200/JCO.1992.10.6.904
  11. 11. Jang RW et al. J Oncol Practice. 2014;10(5):e335-e341. doi:10.1200/JOP.2014.001457
  12. 12. Simmonds PC, et al. B J Cancer 2006 94:7. 2006;94(7):982-999. doi:10.1038/sj.bjc.6603033
  13. 13. Douillard JY et al. Lancet. 2000;355(9209):1041-1047. doi:10.1016/S0140-6736(00)02034-1
  14. 14. de Gramont A et al. J Clin Oncol. 2016;15(2):808-815. doi:10.1200/JCO.1997.15.2.808
  15. 15. O’connell MJ. Cancer. 1989;63:1026-1030. doi:10.1002/1097-0142
  16. 16. Poon MA et al. J Clin Oncol. 2016;7(10):1407-1418. doi:10.1200/JCO.1989.7.10.1407
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

S01 E02

Latest and greatest in metastatic colon cancer – mAbs, MSI status, sidedness and controversies

Open episode on Buzzsprout

Show notes

Topics covered

  1. Background on molecular targeted agents
  2. VEGF-inhibitors
  3. EGFR inhibition
  4. Left vs Right sided colon cancer
  5. MSI-H/dMMR status
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5
  2. 2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z
  3. 3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691
  4. 4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9
  5. 5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060
  6. 6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930
  7. 7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520
  8. 8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174
  9. 9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305
  10. 10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.
  11. 11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570
  12. 12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057
  13. 13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797
  14. 14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105
  15. 15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114
  16. 16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258
  17. 17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19
  18. 18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6
  19. 19. André T et al. NEJM 2020;383(23):2207-2218.
  20. 20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834
  21. 21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015
  22. 22. Tol J et al. NEJM. 2009;360(6):563-572.
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

S01 E03

Localized Colon Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Clinical Presentation, Pathology Evaluation
  2. Chemotherapy Regimens in Adjuvant Setting
  3. Approach to Stage 3
  4. Approach to Stage 2
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Practice Tools for the prognostic of Colorectal Cancer. Accessed April 2, 2022. https://oncologypro.esmo.org/oncology-in-practice/practice-tools/colorectal-cancer-prognosis
  2. 2. Haller DG et al. Ann Oncol. 2015;26(4):715-724. doi:10.1093/ANNONC/MDV003
  3. 3. Babcock BD et al. Ann Surg Oncol. 2018;25(7):1980-1985. doi:10.1245/S10434-018-6484-8
  4. 4. Moertel CG et al. NEJM. 2010;322(6):352-358. doi:10.1056/NEJM199002083220602
  5. 5. Ribic CM et al. NEJM. 2003;349(3):247-257. doi:10.1056/NEJMOA022289
  6. 6. Haller DG et al. J Clin Oncol. 2005;23(34):8671-8678. doi:10.1200/JCO.2004.00.5686
  7. 7. Kuebler JP et al. J Clin Oncol. 2007;25(16):2198-2204. doi:10.1200/JCO.2006.08.2974
  8. 8. André T et al. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771
  9. 9. Sargent DJ et al. J Clin Oncol. 2005;23(34):8664-8670. doi:10.1200/JCO.2005.01.6071
  10. 10. Kannarkatt J et al. J Oncol Pract. 2017;13(4):233-241. doi:10.1200/JOP.2016.017210
  11. 11. Grothey A et al. NEJM. 2018;378(13):1177-1188.
  12. 12. André T et al. Lancet Oncol. 2020;21(12):1620-1629. doi:10.1016/S1470-2045(20)30527-1
  13. 13. André T et al. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771
  14. 14. André T et al. Oxaliplatin, NEJM 2009;350(23):2343-2351. doi:10.1056/NEJMOA032709
  15. 15. Buyse M et al. Stat Methods Med Res. 2008;17(5):467-475. doi:10.1177/0962280207081864
  16. 16. Sargent D et al. Eur J Cancer. 2011;47(7):990. doi:10.1016/J.EJCA.2010.12.015
  17. 17. Gray R et al. Lancet. 2007;370(9604):2020-2029. doi:10.1016/S0140-6736(07)61866-2
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

S01 E04

IDEA Trial Discussion

Open episode on Buzzsprout

Show notes

Topics covered

  1. Background/Methods
  2. Non-inferiority Trial Design
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Grothey A et al. NEJM. 2018;378:1177-1188. doi:10.1056/NEJMoa1713709
  2. 2. Andre PT et al. Lancet Oncol. 2020;21(12):1620-1629. doi:10.1016/S1470-2045(20)30527-1
  3. 3. Mauri LM and D’Agostino RB. NEJM. 2017;377:1357-1367. doi: 10.1056/NEJMra1510063
  4. 4. Hahn S. Korean J Pediatr. 2012;55(11):403-407. doi: 10.3345/kjp.2012.55.11.403
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

S01 E05

Localized Esophageal and Gastric Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Anatomy of the Upper GI Tract
  2. Diagnosis, Staging Work-up
  3. Neoadjuvant Chemoradiation for Esophageal/EGJ
  4. Perioperative and Adjuvant Gastric/EGJ
  5. Checkmate 577 discussion
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Ronellenfitsch U et al. Eur J Cancer. 2019;123:101-111. doi:10.1016/J.EJCA.2019.10.001
  2. 2. Ohn J et al. NEJM 2009;345(10):725-730. doi:10.1056/NEJMOA010187
  3. 3. Ell C et al. Gastroenterology. 2000;118(4):670-677. doi:10.1016/S0016-5085(00)70136-3
  4. 4. al-Sarraf M et al. J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277
  5. 5. Oba K et al. J Natl Cancer Inst. 2013;105(21):1600-1607. doi:10.1093/JNCI/DJT270
  6. 6. Bang YJ et al. Lancet. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4
  7. 7. Smalley SR et al. Journal of Clinical Oncology. 2012;30(19):2327. doi:10.1200/JCO.2011.36.7136
  8. 8. Petrelli F et al. Eur J Cancer. 2017;76:8-16. doi:10.1016/J.EJCA.2017.01.032
  9. 9. Kelly RJ et al. NEJM 2021;384(13):1191-1203. doi:10.1056/NEJMOA2032125
  10. 10. Al-Batran SE et al. The Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1
  11. 11. al-Sarraf M et al.J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277
  12. 12. Cunningham D et al. NEJM. 2009;355(1):11-20. doi:10.1056/NEJMOA055531
  13. 13. JS C, et al. JAMA. 1999;281(17):535-547. doi:10.1001/JAMA.281.17.1623
  14. 14. Park SH et al. J Clin Oncol. 2021;32(3):368-374. doi: 10.1016/j.annonc.2020.11.017
  15. 15. Lee J et al. Journal of Clinical Oncology. 2012;30(3):268-273. doi:10.1200/JCO.2011.39.1953
  16. 16. Cats A et al. The Lancet Oncology. 2018;19(5):616-628. doi:10.1016/S1470-2045(18)30132-3
  17. 20. van Hagen P et al. NEJM. 2012;366(22):2074-2084. doi: 10.1056/NEJMoa1112088
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

S01 E06

Metastatic Gastroesophageal Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Principles of management
  2. Key chemotherapy regimens
  3. Immunotherapy/HER-2 Directed Approach
  4. Alpha spending, hierarchical statistical design
  5. Later line approach and bottom lines to approach
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Veer E ter et al. J Natl Cancer Inst. 2016;108(10). doi:10.1093/JNCI/DJW166
  2. 2. Guimbaud R et al. J Clin Oncol. 2014;32(31):3520-3526. doi:10.1200/JCO.2013.54.1011
  3. 3. Cunningham D et al. NEJM. 2008;358(1):36-46. DOI: 10.1056/NEJMoa073149
  4. 4. Wagner AD et al. J Clin Oncol. 2006;24(18):2903-2909. doi:10.1200/JCO.2005.05.0245
  5. 5. Janjigian YY et al. Lancet Oncol. 2020;21(6):821-831. doi:10.1016/S1470-2045(20)30169-8
  6. 6. ter Veer et al. Int J Cancer. 2018;143(2):438-448. doi:10.1002/IJC.31325
  7. 7. Doki Y et al. NEJM. 2022;386(5):449-462. doi: 10.1056/NEJMoa2111380
  8. 8. Shitara K et al. NEJM. 2020;382(25):2419-2430. DOI: 10.1056/NEJMoa2004413
  9. 9. Wilke H et al. The Lancet Oncology. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6
  10. 10. Chao J et al. JAMA Oncol. 2021;7(6):895-902. doi:10.1001/JAMAONCOL.2021.0275
  11. 11. Janjigian YY et al. Lancet. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2
  12. 12. Shitara K et al. Nature. 2022;603:7903. doi:10.1038/s41586-022-04508-4
  13. 13. Sun JM et al. The Lancet. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4
  14. 14. Shitara K, et al. JAMA Oncology. 2020;6(10):1571-1580. doi:10.1001/JAMAONCOL.2020.3370
  15. 15. Bang YJ et al. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

S01 E07

Metastatic Pancreatic Cancer – An Overview

Open episode on Buzzsprout

Show notes

Topics covered

  1. Natural history of disease, presentation, and diagnosis
  2. Principles of management
  3. Landmark clinical trials
  4. Targeted therapy options as of 2022
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Golan T et al. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMOA1903387
  2. 2. Von Hoff DD et al. N Engl J Med. 2013;369(18):1691-1703. doi:10.1056/NEJMOA1304369
  3. 3. Conroy T et al. N Engl J Med. 2011;364(19):1817-1825. doi:10.1056/NEJMOA1011923
  4. 4. Carmichael J et al. Br J Cancer. 1996;73(1):101. doi:10.1038/BJC.1996.18
  5. 5. Casper ES et al. Investig New Drugs 1994 121. 1994;12(1):29-34. doi:10.1007/BF00873232
  6. 6. Rothenberg ML et al. Ann Oncol. 1996;7(4):347-353. doi:10.1093/OXFORDJOURNALS.ANNONC.A010600
  7. 7. New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development | Division of Cancer Prevention. https://prevention.cancer.gov/news-and-events/blog/new-onset-diabetes-cohort. Accessed June 13, 2022.
  8. 8. McGuigan A et al. W J Gastroenterology. 2018;24(43):4846-4861. doi:10.3748/WJG.V24.I43.4846
  9. 9. Kamisawa T et al. Pancreatic cancer. Lancet. 2016;388(10039):73-85. doi:10.1016/S0140-6736(16)00141-0
  10. 10. Siegel RL et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/CAAC.21708
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E08

Localized Pancreatic Cancer – A View From 1000 feet

Open episode on Buzzsprout

Show notes

Topics covered

  1. Differential for pancreatic lesion, staging of adenocarcinoma
  2. Surgical considerations, post-surgical complications
  3. Historical adjuvant evidence
  4. An argument for neoadjuvant systemic therapy
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Fietkau et al. Rl. J Clin Oncol 2022;40(16_suppl) doi:10.1200/JCO.2022.40.16_SUPPL.4008
  2. 2. Conroy T et al. F NE JMe. 2018;379(25):2395-2406. doi:10.1056/NEJMOA1809775
  3. 3. Tempero MA et al. J Clin Oncol. 2019;37(15_suppl) doi:10.1200/JCO.2019.37.15_SUPPL.4000
  4. 4. Neoptolemos JP et al. The Lancet. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6/ATTACHMENT/46BFFE67-D3AE-4DEA-822B-4A2CE28139FD/MMC1.PDF
  5. 5. Liao WC et al. Lancet Oncol. 2013;14(11):1095-1103. doi:10.1016/S1470-2045(13)70388-7
  6. 6. van Laethem JL et al. J Clin Oncol. 2010;28(29):4450-4456. doi:10.1200/JCO.2010.30.3446
  7. 7. Evans DB et al. Annals of Surgery. 2000;232(5):727. doi:10.1097/00000658-199912000-00006
  8. 8. Kaiser M, Ellenberg S. Arch Surg. 1985;120(8):899-903. doi:10.1001/ARCHSURG.1985.01390320023003
  9. 9. van Dam JL et al. Eur J Cancer. 2022;160:140-149. doi:10.1016/J.EJCA.2021.10.023
  10. 10. Versteijne E et al. J Clin Oncol. 2022;40(11):1220-1230. doi:10.1200/JCO.21.02233
  11. 11. Neoptolemos et al. NEJM. 2004;350(12):1200-1210. doi:10.1056/NEJMOA032295
  12. 12. Neoptolemos JP et al. Lancet. 2001;358(9293):1576-1585. doi:10.1016/S0140-6736(01)06651-X
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E09

Metastatic Cholangiocarcinoma

Open episode on Buzzsprout

Show notes

Topics covered

  1. Metastatic Cholangiocarcinoma
  2. Overview of nomenclature, etiology and presentation
  3. Management of symptoms and prognosis
  4. Systemic therapy in the first line
  5. Second line and biomarker driven management
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Marabelle A et al.. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105
  2. 2. Lamarca A et al. The Lancet Oncology. 2021;22(5):690-701. doi:10.1016/S1470-2045
  3. 3. Zia MI, Siu LL, et al. Journal of Clinical Oncology. 2005;23(28):6982-6991. doi:10.1200/JCO.2005.06.679
  4. 4. Phelip JM et al. J Clin Oncol. 2022;40(3):262-271. doi:10.1200/JCO.21.00679
  5. 5. Valle J et al. NEJM. 2010;362(14):1273-1281. doi:10.1056/NEJMOA0908721
  6. 6. Oh DY et al. NEJM Evidence. Published online June 1, 2022. doi:10.1056/EVIDoa2200015
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E09A

Daroxonrasib: A KRAS(on) inhibitor (mini-discussion)

Open episode on Buzzsprout

Show notes

Topics covered

  1. RAS as an oncogene
  2. The undruggable RAS
  3. KRAS G12C as a specific exception
  4. Daroxonrasib as a pan RAS(On) inhibitor
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Wang-Gillam A , et al. Eur J Cancer. 2019;108:78-87. doi:10.1016/j.ejca.2018.12.007
  2. 2. O’Reilly EM et al. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMOA2605555
  3. 3. Cregg J et al. J Med Chem. 2025;68(6):6041-6063. doi:10.1021/ACS.JMEDCHEM.4C02313/
  4. 4. Fakih MG et al. Engl J Med. 2023;389(23):2125-2139. doi:10.1056/NEJMOA2308795
  5. 5. de Langen AJ, et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0
  6. 6. Cox AD et al. Nat Rev Drug Discovery 2014 13:11. 2014;13(11):828-851. doi:10.1038/nrd4389
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E10

Localized Cholangiocarcinoma

Open episode on Buzzsprout

Show notes

Topics covered

  1. Overview of intrahepatic, perihilar, distal cholangiocarcinoma
  2. Overview of gall bladder adenocarcinoma
  3. Adjuvant chemoradiation and chemotherapy options
  4. Per-protocol, intention to treat analysis, historical controls
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022;40(18):2048-2057. doi:10.1200/JCO.21.02568
  2. 2. Primrose JN, Neoptolemos J, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X
  3. 3. Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192-202. doi:10.1002/BJS.10776
  4. 4. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1). doi:10.1053/J.GASTRO.2012.04.008
  5. 5. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015-1027. doi:10.1200/JCO.18.02178
  6. 6. Edeline J, Bonnetain F, Phelip JM, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. https://doi.org/101200/JCO2017354_suppl225. 2017;35(4_suppl):225-225. doi:10.1200/JCO.2017.35.4_SUPPL.225
  7. 7. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-v37. doi:10.1093/ANNONC/MDW324
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E11

Rectal Cancer – An Overview of the Challenges and Basics of Management

Open episode on Buzzsprout

Show notes

Topics covered

  1. Anatomy, definitions, and unique considerations vs colon cancer
  2. Surgical modalities and patterns of failure
  3. Perioperative radiation and chemoradiation
  4. Evidence to support adjuvant systemic therapy
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Delitto D et al. JNCI Journal of the National Cancer Institute. 2018;110(5):460. doi:10.1093/JNCI/DJX228
  2. 2. Bujko K et al. Br J Surg. 2006;93(10):1215-1223. doi:10.1002/BJS.5506
  3. 3. Hong YS et al. J Clin Oncol 2018;36(15_suppl):3501 doi:10.1200/JCO.2018.36.15
  4. 4. Hong YS et al. Journal of Clinical Oncology. 2019;37(33):3111-3123. doi:10.1200/JCO.19.00016
  5. 5. Gérard JP et al. J Clin Oncol. 2006;24(28):4620-4625. doi:10.1200/JCO.2006.06.7629
  6. 6. Roh MS et al. J Clin Oncol. 2009;27(31):5124-5130. doi:10.1200/JCO.2009.22.0467
  7. 7. Sauer R et al. NEJM 2004;351(17):1731-1740. doi:10.1056/NEJMOA040694
  8. 8. Erlandsson J et al. Lancet Oncol. 2017;18(3):336-346. doi:10.1016/S1470-2045(17)30086-4
  9. 9. Folkesson J et al. J Clin Oncol. 2005;23(24):5644-5650. doi:10.1200/JCO.2005.08.144
  10. 10. Sebag-Montefiore D et al. Lancet. 2009;373(9666):811-820. doi:10.1016/S0140-6736(09)60484-0
  11. 11. Kapiteijn E et al. N Engl J Med. 2001;345(9):638-646. doi:10.1056/NEJMOA010580
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E12

Rectal Cancer – TNT (Total Neoadjuvant Therapy) and Dostarlimab

Open episode on Buzzsprout

Show notes

Topics covered

  1. RAPIDO Trial
  2. PRODIGE-23 Trial
  3. OPRA Trial
  4. Evidence for non-operative potential in MSI-H tumors with immune checkpoint inhibition
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Garcia-Aguilar J, et al. Organ. Journal of Clinical Oncology. 2022;18. doi:10.1200/JCO.22.00032
  2. 2. Cercek A et al. NEJM. 2022;386(25):2363-2376. doi:10.1056/NEJMOA2201445
  3. 3. July 10, 2020 - EPOV Christopher Hallemeier - The ASCO Post. Accessed August 30, 2022. https://ascopost.com/issues/july-10-2020/epov-christopher-hallemeier/
  4. 4. Thompson H et al. J Clin Oncol. 2021;39(15_suppl). doi:10.1200/JCO.2021.39.15_SUPPL.3509
  5. 5. Conroy T et al. Lancet Oncol. 2021;22(5):702-715. doi:10.1016/S1470-2045(21)00079-6
  6. 6. Bahadoer RR et al. Lancet Oncol. 2021;22(1):29-42. doi:10.1016/S1470-2045(20)30555-6
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E13

Anal Squamous Cell Carcinoma

Open episode on Buzzsprout

Show notes

Topics covered

  1. Overview of disease site
  2. Management of localized disease
  3. Surveillance
  4. Metastatic Disease
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2021;32(9):1087-1100. doi:10.1016/j.annonc.2021.06.015
  2. 2. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446-453. doi:10.1016/S1470-2045(17)30104-3
  3. 3. Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology. 2020;38(22):2510-2518. doi:10.1200/JCO.19.03266
  4. 4. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. https://doi.org/101200/JCO19961492527. 2016;14(9):2527-2539. doi:10.1200/JCO.1996.14.9.2527
  5. 5. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013;14(6):516-524. doi:10.1016/S1470-2045(13)70086-X
  6. 6. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123. doi:10.1038/SJ.BJC.6605605
  7. 7. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum. 1974;17(3):354-356. doi:10.1007/BF02586980
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S01 E14

Ampullary Carcinoma (Mini Discussion)

Open episode on Buzzsprout

Show notes

Topics covered

  1. Clinical presentation and work-up
  2. Intestinal and pancreatobiliary subtypes
  3. Role of perioperative therapy
  4. Considerations for metastatic disease
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Neoptolemos JP et al. JAMA. 2010;304(10):1073-1081. doi:10.1001/JAMA.2010.1275
  2. 2. Smeenk HG et al.. Ann Surg. 2007;246(5):734-740. doi:10.1097/SLA.0B013E318156EEF3
  3. 3. Chang DK , et al. J Clin Oncol. 2013;31(10):1348-1356. doi:10.1200/JCO.2012.46.8868
  4. 4. Schueneman A et al. Br J Cancer. 2015;113(1):64-68. doi:10.1038/BJC.2015.172
  5. 5. Chiorean EG et al. Journal of the National Comprehensive Cancer Network. 2023;21(7):753-782. doi:10.6004/JNCCN.2023.0034
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology